Room: Sorrell Room 2014

• Chair: Hui Zhang, PhD, Johns Hopkins University
• Co-chair: Mamie Lih, PhD, Johns Hopkins University
• Tao Liu, PhD, Pacific Northwest National Laboratory (PNNL)
• DMCC Statistician: Ying Huang, PhD, Fred Hutchinson Cancer Center
• DMCC Staff: Stephanie Page-Lester, Fred Hutchinson Cancer Center
• NCI PD: Matt Young PhD, National Cancer Institute

Agenda

Suggested Discussion Points:

1. The Role of Proteogenomics in Early Cancer Detection:

• How proteogenomic integration can improve early detection methods for cancer.
• Current limitations and advancements in using proteogenomics to identify early-stage cancer markers.
• Comparing proteogenomic approaches to traditional diagnostic methods.

2. Identifying Novel Biomarkers through Proteogenomics:

• The potential of proteogenomics to discover new, highly specific biomarkers for various cancers.
• Case studies of successful biomarker identification through proteogenomic methods.
• Overcoming challenges in translating biomarkers from discovery to clinical use.

3. Proteogenomics in Liquid Biopsy for Early Detection:

• Advances in using proteogenomic data from liquid biopsies for early cancer detection.
• Sensitivity and specificity considerations when using circulating proteins and nucleic acids as biomarkers.
• The potential of liquid biopsy combined with proteogenomics in tracking tumor evolution.

4. Technological and Analytical Innovations in Proteogenomics:

• Breakthroughs in mass spectrometry, sequencing, and bioinformatics that are advancing biomarker discovery.
• The role of machine learning and AI in interpreting proteogenomic data for early detection.
• Integrating multi-omics data (genomics, transcriptomics, proteomics) to enhance early detection strategies.

5. Challenges in Clinical Translation of Proteogenomic Biomarkers:

• Regulatory hurdles and validation requirements for bringing proteogenomic biomarkers to clinical practice.
• Strategies for overcoming the variability in proteogenomic data across different cancer types and patient populations.
• Ethical considerations around early cancer detection and biomarker discovery, including patient consent and data privacy.

6. Collaborative Efforts in Proteogenomics for Early Cancer Detection:

• The importance of collaboration between research institutions, pharmaceutical companies, and healthcare providers.
• Opportunities for large-scale, global proteogenomics initiatives to accelerate biomarker discovery.
• Building databases and sharing resources for a collective approach to early cancer detection research.